Matthew Birnbaum

Matthew Birnbaum is a Research Specialist at Regeneron Pharmaceuticals, Inc., where he has been involved in significant projects related to genomic engineering technologies. His tenure at Regeneron lasted from August 2013 to October 2019, during which he worked in two primary areas: formulation development and genomic engineering technologies. In formulation development, he focused on drug stability assessments for molecules in clinical trials, while in genomic engineering, he contributed to developing methods for targeted enzyme replacement therapy and endosomal escape techniques.1

Prior to his role at Regeneron, Birnbaum gained experience as an undergraduate researcher at various laboratories, including the Mark Goodman Laboratories at Emory University, where he synthesized molecules for PET radiotracers, and the Raymond Schinazi Laboratories, focusing on hepatitis C medications.1 He has also held positions at bioStrategies Group and Charles River Associates, where he worked as a consultant and senior associate, respectively.1

Birnbaum's academic background includes a strong foundation in chemistry, as evidenced by his honors and awards during his studies at Emory University, where he graduated summa cum laude. His research contributions have been recognized with awards for excellence in undergraduate research.1